The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2016
At a glance
- Drugs Ruboxistaurin (Primary)
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 09 Nov 2012 Planned number of patients changed from 300 to 309.
- 15 Dec 2009 Planned end date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 15 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.